NCT05838521

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Yale University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.

Detailed description

This is an open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in subjects with recurrent or persistent cervical cancer.

Conditions

• Cervical Cancer

Interventions

Type	Name	Description
DRUG	Sacituzumab govitecan	This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).

Timeline

• Start date: 2023-06-02
• Primary completion: 2026-06-01
• Completion: 2028-06-01
• First posted: 2023-05-01
• Last updated: 2026-02-06

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study